Shiseido Acquires Breakthrough Technology from Olivo Laboratories
Shiseido Company, Limited (TOKYO:4911) (“Shiseido”), a leading global
cosmetics company, announced today that its regional headquarters and
consolidated subsidiary, Shiseido Americas Corporation (“Shiseido
Americas”), has acquired substantially all of the assets of Olivo
Laboratories, LLC (“Olivo”). Olivo is a Polaris Partners-backed
Massachusetts-based startup advancing the dermatological field through
proprietary biomaterials technology, including its pioneering XPLTM*
“Second Skin” technology. The CEO is Polaris Partner Amy Schulman. Terms
of the transaction were not disclosed.
*Cross-linking Polymer Layer
Olivo’s patented approach creates a breathable, flexible and nearly
invisible artificial skin, that offers a number of benefits previously
unachievable through traditional cosmetics or even cosmetic surgery.
Olivo was founded by renowned scientists including Dr. Robert Langer*,
David H. Koch Institute Professor at Massachusetts Institute of
Technology, Dr. Rox Anderson, Head of the Wellman Center of
Photomedicine at Massachusetts General Hospital, and Dr. Dan Anderson,
Associate Professor of Chemical Engineering at Massachusetts Institute
of Technology. The Olivo research and development team will join the
Shiseido Americas organization as part of the transaction.
* Dr. Langer received more than 220 awards including the Charles Stark Draper Prize, United States National Medal of Science, Queen Elizabeth Prize for Engineering and the 2014 Kyoto Prize.
This acquisition is the latest in a series of initiatives supported by Shiseido and its Global Innovation Center to further expand its global beauty innovation footprint. Combining Olivo's innovative technology with Shiseido’s research and development capabilities marks a significant leap forward in the emerging realm of "skin shape correction,” and paves the way for the development of products that provide instant and significantly enhanced skincare and suncare.
Masahiko Uotani, President and CEO of Shiseido, said, “Our transaction with Olivo is an exciting next step in our ongoing pursuit to create entirely new categories of beauty products at a global scale as a part of our VISION 2020, middle to long term strategy. Olivo’s ground-breaking ‘Second Skin’ technology will join Shiseido’s already robust innovation portfolio, which includes the personalization technology startup MATCHCo, the artificial intelligence-empowered beauty company Giaran, and our own Shiseido-developed OPTUNE, a digital, personalized skincare platform. We look forward to welcoming our new colleagues at Olivo and benefiting from the expertise of Dr. Langer as we continue to reinvent the beauty industry and to create new products tailored to each of our customers’ unique and personal ideals of beauty.”
Dr. Robert Langer, Co-Founder of Olivo, stated, “We use science to break down and tackle problems. Here, we were able to really solve a pervasive problem and create a platform with novel biomaterials. Shiseido provides an exciting opportunity to continue executing on that mission and to further demonstrate the many capabilities of our XPL platform. We look forward to the future when we unlock the XPL Second Skin’s full potential across a range of different applications.”
Amy Schulman, CEO of Olivo, noted that, “We are delighted to work with Shiseido, a company that has the vision, resources and talent to be pioneers in beauty science and to create a new standard for skincare in the beauty industry.”
Marc Rey, President and CEO of Shiseido Americas, added, “As the evolution of beauty-dedicated technologies continues apace, it becomes increasingly important for companies like Shiseido Group to take an external view when it comes to innovation and product development. By joining forces with leaders in scientific research like Dr. Langer and the Olivo team, we will continue to meet the demands of the consumer while offering the very latest advances in science and beauty.”
About Shiseido Company, Limited
Shiseido was founded in 1872 as the first Western-style pharmacy in Japan. The business gradually evolved into a cosmetics company, offering people the most advanced technology and the finest aesthetics available in the East or the West. Now, known globally as the premier cosmetics company with roots in Japan the name Shiseido has come to represent the world’s highest standard of quality in beauty. Shiseido’s global selection of skincare, makeup and fragrance includes a high-performance category for special skincare, and a brightening line. Shiseido offers products for professional beauty salons and hairdressers, as well as body care, suncare and a skincare line for men. Fiercely contemporary and innovative with over 140 years in business, the Shiseido group brands are now sold in over 120 countries. For more information, please visit http://group.shiseido.com/.
About Olivo Laboratories, LLC
Olivo Laboratories was founded to answer the unmet needs in the dermatological field, providing solutions for skin-related medical conditions, through the development of proprietary biomaterials technologies. Spun out of “Living Proof” in 2015, the company seeks to create benchmark solutions through perfectly engineered products that focus on the skin’s medical and cosmetic problems.
For Shiseido Headquarters
Global Communications Department
For Shiseido Americas:
Jadzia Zielinski Tirsch, 212-805-2357
SVP, Corporate Communications
For Olivo Laboratories:
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Rimini Street Launches New Solutions that Further Extend the Life and Value of Enterprise Software as a Foundation for Innovation24.4.2018 16:00 | Pressemelding
Rimini Street, Inc . (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the first offerings in a family of solutions designed to provide improved competitive advantage to organizations with mature and valuable enterprise software investments that can be used as a foundation for innovation. Rimini Street’s new solutions can enable an organization to quickly and cost-effectively modernize their current enterprise software with the latest desired features and capabilities, future-proof their technical platforms against yet-unknown technology changes, and secure their systems against a constantly evolving threat environment. Rimini Street’s new solutions enable organizations to leverage their existing systems as a solid foundation for an innovative hybrid IT strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/
Novaliq to Present Scientific and Clinical Research During the 2018 Association for Research in Vision and Ophthalmology Meeting in Honolulu, HI24.4.2018 15:53 | Pressemelding
Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Meeting in Honolulu, HI (April 29-May 3). The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With the collection of posters, Novaliq will share clinical and pre-clinical data on its EyeSol® drug delivery technology and provide insights into the mode of action of its NOV03/NovaTears® water-free therapy for the treatment of dry eye disease (DED). Furthermore, Novaliq will present its first pre-clinical efficacy data in glaucoma. Scientific posters supported by Novaliq will include: “Influence of perfluorohexyloctane containing eye drops on tear film thickness in patients with mild to moderate dry eye disease.” Authors: Garhöfer G., Schm
Temasys Communications and Appian Partner to Power Real-Time Communications in the Contact Center24.4.2018 15:00 | Pressemelding
Temasys Communications announced today that Appian has integrated with the Temasys Skylink technology, enabling real-time communications, including chat and co-browsing, in Appian’s new Intelligent Contact Center (ICC) Platform. “For our contact center customers, omni-channel communications are essential. Appian is working with Temasys to provide contact centers with real-time communication channels such as chat and co-browsing via the Temasys versatile SDKs,” said Arturo Oliver, Senior Director of Product Strategy at Appian. Temasys Skylink APIs will be compatible with the Appian Intelligent Contact Center Platform, making it easy for Appian customers to add real-time communication to their applications, including chat, voice, video and co-browsing. These integrations enable users to visit a website, begin a chat session that seamlessly escalates to a voice call and extend to co-browsing — all without changing apps or establishing a new connection. “We’re thrilled to work with Appian
PPG Reports Sustainability Progress, New 2025 Goals24.4.2018 13:07 | Pressemelding
PPG (NYSE:PPG) today released its 2017 Corporate Sustainability Report, which details the company’s continued progress in strengthening its sustainable operations in 2017 and the launch of new, aggressive sustainability goals it aims to achieve by 2025. The report is available at sustainability.ppg.com. “PPG’s sustainability efforts go beyond product innovations to extend to our customers’ operations and the communities in which we operate,” said Mark Cancilla, PPG vice president, environment, health and safety. “We are encouraged by our progress in 2017 and excited about our new goals, which are representative of the challenges and opportunities of our current business portfolio.” The company achieved the following progress in 2017: 32 percent of sales from products that provide customers with a sustainable advantage, an increase of 60 percent since 2012. This includes the unveiling of multiple products that provide a sustainable solution, such as Sigma Air Pure, a revolutionary bio-b
Bioiberica Approves Its Combined Drug for Osteoarthritis in Five More European Countries24.4.2018 12:17 | Pressemelding
Bioiberica's combination of chondroitin sulphate and glucosamine hydrochloride, a slow action drug to treat osteoarthritis symptoms, was approved as an ethical drug in France, Austria, Hungary, Poland, and Finland through a mutual recognition process from Spain. ‘This approval confirms that Drug Agencies from different countries attest to the effectiveness and safety of the combination of pharmaceutical grade chondroitin sulphate and glucosamine hydrochloride. This drug has proven to reduce pain and improve mobility in people affected by knee osteoarthritis which, due to its safety profile, could also be used as an alternative by those patients with cardiovascular or gastrointestinal problems who should not be prescribed anti-inflammatory drugs chronically’, stated Dr Juan Gispert, Bioiberica's R&D director. The principle study that guarantees its effectiveness is the MOVES clinical trial, published in the Annals of the Rheumatic Diseases, which concludes that the combination of chondr
Asuragen to Present at World CB & CDx Europe Summit in London, UK24.4.2018 12:00 | Pressemelding
Asuragen, Inc., a molecular diagnostics company delivering easy to use products for complex testing in genetics and oncology, announced that its senior vice president of commercial operations, Colin Hill, will chair a roundtable discussion during the 2018 World Clinical Biomarkers & Companion Diagnostic (CB & CDx) Europe Summit taking place May 1-3 in London, UK. The session will focus on the imminent changes to the regulatory environment in Europe and the implications for pharmaceutical and diagnostic companies collaborating to advance precision medicine. “Precision medicine is becoming a reality around the world, and the regulations that guide it are rapidly evolving,” said Hill. “It is essential that we build close collaboration between the pharmaceutical, medical device and in vitro diagnostics industry if we are going to successfully navigate this new environment. While our success will definitely leverage learnings from the US experience, we will have to broaden our thinking as w